New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 10, 2015, Pages 972-979

  Shelton, E ^a,b   Chaudrey, K ^a   Sauk, J ^a,b   Khalili, H ^a,b   Masia, R ^a,b   Nguyen, D D ^a,b   Yajnik, V ^a,b   Ananthakrishnan, A N ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; CERTOLIZUMAB PEGOL; INFLIXIMAB; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; ARTICLE; AUTOIMMUNITY; BIOLOGICAL THERAPY; BODY MASS; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DRUG SAFETY; FEMALE; FOLLOW UP; GENDER; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; INFLAMMATORY BOWEL DISEASE; LIVER BIOPSY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; ULCERATIVE COLITIS; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; DRUG-INDUCED LIVER INJURY; INFLAMMATORY BOWEL DISEASES; LIVER FUNCTION TEST; METABOLISM; PROCEDURES; RECURRENT DISEASE;

ADULT; ALANINE TRANSAMINASE; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL THERAPY; COHORT STUDIES; DRUG-INDUCED LIVER INJURY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFLAMMATORY BOWEL DISEASES; LIVER FUNCTION TESTS; MALE; POLYETHYLENE GLYCOLS; RECURRENCE; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84927786459     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13159     Document Type: Article

References (31)

1. Rutgeerts P, Van Assche G, Vermeire S,. Review article: infliximab therapy for inflammatory bowel disease-seven years on. Aliment Pharmacol Ther 2006; 23: 451-63.
2. Devaraj B, Kaiser AM,. Surgical management of ulcerative colitis in the era of biologicals. Inflamm Bowel Dis 2015; 21: 208-20.
3. Rutgeerts P, Sandborn WJ, Feagan BG, et al,. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
4. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P,. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 644-59; quiz 660.
5. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
6. Lichtenstein GR, Yan S, Bala M, Hanauer S,. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004; 99: 91-6.
7. Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR,. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 2003; 98: 2232-8.
8. ™ registry. Am J Gastroenterol 2012; 107: 1409-22.
9. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V,. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85.
10. Ramos-Casals M, Brito-Zeron P, Soto M-J, Cuadrado M-J, Khamashta MA,. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008; 22: 847-61.
11. FDA. Remicade (Infliximab) Prescribing Information, March 2013; 1-60. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/103772s5345lbl.pdf (accessed 14 March 2012).
12. Saleem G, Li SC, MacPherson BR, Cooper SM,. Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: comment on the article by Charles et al. Arthritis Rheum 2001; 44: 1966-8.
13. Germano V, Picchianti Diamanti A, Baccano G, et al,. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005; 64: 1519-20.
14. Tobon GJ, Canas C, Jaller J-J, Restrepo J-C, Anaya J-M,. Serious liver disease induced by infliximab. Clin Rheumatol 2007; 26: 578-81.
15. Ozorio G, McGarity B, Bak H, Jordan AS, Lau H, Marshall C,. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust 2007; 187: 524-6.
16. Thiefin G, Morelet A, Heurgue A, Diebold M-D, Eschard J-P,. Infliximab-induced hepatitis: absence of cross-toxicity with etanercept. Joint Bone Spine 2008; 75: 737-9.
17. Carlsen KM, Riis L, Madsen OR,. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. Clin Rheumatol 2009; 28: 1001-3.
18. Adar T, Mizrahi M, Pappo O, Scheiman-Elazary A, Shibolet O,. Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol 2010; 44: e20-2.
19. Goujon C, Dahel K, Berard F, Guillot I, Gunera-Saad N, Nicolas J-F,. Autoimmune hepatitis in two psoriasis patients treated with inflixmab. J Am Acad Dermatol 2010; 63: e43-4.
20. Haennig A, Bonnet D, Thebault S, Alric L,. Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab. Gastroenterol Clin Biol 2010; 34: e7-8.
21. Doyle A, Forbes G, Kontorinis N,. Autoimmune hepatitis during infliximab therapy for Crohn's disease: a case report. J Crohns Colitis 2011; 5: 253-5.
22. Björnsson ES, Gunnarsson BI, Gröndal G, et al,. Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clin Gastroenterol Hepatol 2015; 13: 602-8.
23. Ghabril M, Bonkovsky HL, Kum C, et al,. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol 2013; 11: 558-64.
24. Cheng AG, Oxford EC, Sauk J, et al,. Impact of mode of delivery on outcomes in patients with perianal Crohn's disease. Inflamm Bowel Dis 2014; 20: 1391-8.
25. de Silva PSA, Nguyen DD, Sauk J, Korzenik J, Yajnik V, Ananthakrishnan AN,. Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease. Aliment Pharmacol Ther 2012; 36: 459-66.
26. Desai A, Zator ZA, de Silva P, et al,. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 309-15.
27. Oxford EC, Nguyen DD, Sauk J, et al,. Impact of coexistent celiac disease on phenotype and natural history of inflammatory bowel diseases. Am J Gastroenterol 2013; 108: 1123-9.
28. Benichou C, Danan G, Flahault A,. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46: 1331-6.
29. Subramaniam K, Chitturi S, Brown M, Pavli P,. Infliximab-induced autoimmune hepatitis in Crohn's disease treated with budesonide and mycophenolate. Inflamm Bowel Dis 2011; 17: E149-50.
30. Riad H, Abu Shaikha S, Ansari Al H, Naama Al K, Sada Al H, Mansoori Al M,. Hepatitis and lupus-like syndrome during infliximab therapy for psoriasis. Case Rep Dermatol 2013; 5: 219-24.
31. Grasland A, Sterpu R, Boussoukaya S, Mahe I,. Autoimmune hepatitis induced by adalimumab with successful switch to abatacept. Eur J Clin Pharmacol 2012; 68: 895-8.